Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ischemic Heart Disease

  Free Subscription

Articles published in Cardiovasc Res

Retrieve available abstracts of 42 articles:
HTML format

Single Articles

    August 2021
  1. DAVIDSON SM, Padro T, Bollini S, Vilahur G, et al
    Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart.
    Cardiovasc Res. 2021;117:2161-2174.
    PubMed     Abstract available

  2. PORSCH F, Mallat Z, Binder CJ
    Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies.
    Cardiovasc Res. 2021 Aug 27. pii: 6358718. doi: 10.1093.
    PubMed     Abstract available

  3. SAGRIS M, Antonopoulos AS, Theofilis P, Oikonomou E, et al
    Risk factors profile of young and older patients with Myocardial Infarction.
    Cardiovasc Res. 2021 Aug 6. pii: 6343454. doi: 10.1093.
    PubMed     Abstract available

    July 2021
  4. XU JY, Xiong YY, Tang RJ, Jiang WY, et al
    Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction.
    Cardiovasc Res. 2021 Jul 14. pii: 6321229. doi: 10.1093.
    PubMed     Abstract available

  5. NOSALSKI R, Guzik TJ
    IL-15 and IL-7: keys to dysregulated inflammation in acute coronary syndromes.
    Cardiovasc Res. 2021;117:1806-1808.

    June 2021
  6. MANGOLD A, Ondracek AS, Hofbauer TM, Scherz T, et al
    Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction.
    Cardiovasc Res. 2021 Jun 26. pii: 6310009. doi: 10.1093.
    PubMed     Abstract available

    April 2021
  7. YU J, Li J, Leaver PJ, Arnott C, et al
    Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.
    Cardiovasc Res. 2021 Apr 7. pii: 6214523. doi: 10.1093.
    PubMed     Abstract available

    March 2021
  8. ZHAO TX, Ur-Rahman MA, Sage AP, Victor S, et al
    Rituximab in Patients with Acute ST-elevation Myocardial Infarction (RITA-MI): an Experimental Medicine Safety Study.
    Cardiovasc Res. 2021 Mar 30. pii: 6203810. doi: 10.1093.
    PubMed     Abstract available

  9. HEUSCH G, Rassaf T
    Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning?
    Cardiovasc Res. 2021;117:985-986.

    February 2021
  10. TRINDER M, Zekavat SM, Uddin MM, Pampana A, et al
    Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a).
    Cardiovasc Res. 2021 Feb 24. pii: 6149309. doi: 10.1093.

    January 2021
  11. LECOUR S
    Remote ischaemic conditioning modulates platelet reactivity: the need to optimize the therapy is more important than ever before.
    Cardiovasc Res. 2021;117:346-347.

    Sphingosine-1-phosphate receptor-1 (S1PR1) signalling: the homeostatic pathway of the heart.
    Cardiovasc Res. 2021;117:357-359.

  13. KAIER TE, Alaour B, Marber M
    Cardiac troponin and defining myocardial infarction.
    Cardiovasc Res. 2021 Jan 17. pii: 6103159. doi: 10.1093.
    PubMed     Abstract available

  14. FIOLET ATL, Thompson PL, Mosterd A
    Colchicine in coronary disease: another renaissance of an ancient drug.
    Cardiovasc Res. 2021;117:e4-e6.

  15. MUELLER KAL, Langnau C, Gunter M, Poschel S, et al
    Numbers and phenotype of non-classical CD14dimCD16+ monocytes are predictors of adverse clinical outcome in patients with coronary artery disease and severe SARS-CoV-2 infection.
    Cardiovasc Res. 2021;117:224-239.
    PubMed     Abstract available

  16. MAIN A, Robertson-Gray O, Fuller W
    Cyclophilin D palmitoylation and permeability transition: a new twist in the tale of myocardial ischaemia-reperfusion injury.
    Cardiovasc Res. 2021;117:15-17.

  17. AMANAKIS G, Sun J, Fergusson MM, McGinty S, et al
    Cysteine 202 of cyclophilin D is a site of multiple post-translational modifications and plays a role in cardioprotection.
    Cardiovasc Res. 2021;117:212-223.
    PubMed     Abstract available

  18. CORCORAN D, Radjenovic A, Mordi IR, Nazir SA, et al
    Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
    Cardiovasc Res. 2021;117:320-329.
    PubMed     Abstract available

  19. LIMA CORREA B, El Harane N, Gomez I, Rachid Hocine H, et al
    Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts.
    Cardiovasc Res. 2021;117:292-307.
    PubMed     Abstract available

  20. NAKASHIMA Y, Sakai Y, Mizuno Y, Furuno K, et al
    Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease.
    Cardiovasc Res. 2021;117:96-108.
    PubMed     Abstract available

  21. LI Y, Yan H, Guo J, Han Y, et al
    Down-regulated RGS5 by genetic variants impairs endothelial cell function and contributes to coronary artery disease.
    Cardiovasc Res. 2021;117:240-255.
    PubMed     Abstract available

    October 2020
  22. WU X, Reboll MR, Korf-Klingebiel M, Wollert KC, et al
    Angiogenesis After Acute Myocardial Infarction.
    Cardiovasc Res. 2020 Oct 16. pii: 5924555. doi: 10.1093.
    PubMed     Abstract available

    August 2020
  23. PERROTTA S, Carnevale D
    A neuro-humoral activation of RAAS in endothelial dysfunction modulating immunity in heart failure.
    Cardiovasc Res. 2020 Aug 4. pii: 5880579. doi: 10.1093.

    June 2020
  24. ANGIOLILLO DJ, Baber U, Mehran R
    Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.
    Cardiovasc Res. 2020;116:e70-e72.

  25. LI J, Gong Y, Wang W, Yang Q, et al
    Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR.
    Cardiovasc Res. 2020;116:1349-1356.
    PubMed     Abstract available

    May 2020
  26. KAUR A, Mackin ST, Schlosser K, Wong FL, et al
    Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease.
    Cardiovasc Res. 2020;116:1113-1124.
    PubMed     Abstract available

  27. SI R, Zhang Q, Tsuji-Hosokawa A, Watanabe M, et al
    Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.
    Cardiovasc Res. 2020;116:1186-1198.
    PubMed     Abstract available

  28. HOOGENDOORN A, Kok AM, Hartman EMJ, de Nisco G, et al
    Multidirectional wall shear stress promotes advanced coronary plaque development: comparing five shear stress metrics.
    Cardiovasc Res. 2020;116:1136-1146.
    PubMed     Abstract available

  29. GOLLMANN-TEPEKOYLU C, Polzl L, Graber M, Hirsch J, et al
    miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy.
    Cardiovasc Res. 2020;116:1226-1236.
    PubMed     Abstract available

    April 2020
  30. OWENIER C, Hesse J, Alter C, Ding Z, et al
    Novel technique for the simultaneous isolation of cardiac fibroblasts and epicardial stromal cells from the infarcted murine heart.
    Cardiovasc Res. 2020;116:1047-1058.
    PubMed     Abstract available

  31. ROCZKOWSKY A, Chan BYH, Lee TYT, Mahmud Z, et al
    Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.
    Cardiovasc Res. 2020;116:1021-1031.
    PubMed     Abstract available

    March 2020
  32. BAIREY MERZ CN, Pepine CJ, Shimokawa H, Berry C, et al
    Treatment of coronary microvascular dysfunction.
    Cardiovasc Res. 2020;116:856-870.
    PubMed     Abstract available

  33. PADRO T, Manfrini O, Bugiardini R, Canty J, et al
    ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.
    Cardiovasc Res. 2020;116:741-755.
    PubMed     Abstract available

  34. WAHEED N, Elias-Smale S, Malas W, Maas AH, et al
    Sex differences in non-obstructive coronary artery disease.
    Cardiovasc Res. 2020;116:829-840.
    PubMed     Abstract available

  35. SECHTEM U, Brown D, Godo S, Lanza GA, et al
    Coronary microvascular dysfunction in stable ischaemic heart disease (non-obstructive coronary artery disease and obstructive coronary artery disease).
    Cardiovasc Res. 2020;116:771-786.
    PubMed     Abstract available

  36. ONG P, Safdar B, Seitz A, Hubert A, et al
    Diagnosis of coronary microvascular dysfunction in the clinic.
    Cardiovasc Res. 2020;116:841-855.
    PubMed     Abstract available

  37. LAKSHMANAN S, Shekar C, Kinninger A, Dahal S, et al
    Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography.
    Cardiovasc Res. 2020;116:479-482.

  38. SPADACCIO C, Antoniades C, Nenna A, Chung C, et al
    Preventing treatment failures in coronary artery disease: what can we learn from the biology of in-stent restenosis, vein graft failure, and internal thoracic arteries?
    Cardiovasc Res. 2020;116:505-519.
    PubMed     Abstract available

  39. LOU X, Zhao M, Fan C, Fast VG, et al
    N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts.
    Cardiovasc Res. 2020;116:671-685.
    PubMed     Abstract available

  40. GAO C, Wang R, Li B, Guo Y, et al
    TXNIP/Redd1 signalling and excessive autophagy: a novel mechanism of myocardial ischaemia/reperfusion injury in mice.
    Cardiovasc Res. 2020;116:645-657.
    PubMed     Abstract available

  41. BOISGUERIN P, Covinhes A, Gallot L, Barrere C, et al
    A novel therapeutic peptide targeting myocardial reperfusion injury.
    Cardiovasc Res. 2020;116:633-644.
    PubMed     Abstract available

    February 2020
  42. MOLITOR M, Rudi WS, Garlapati V, Finger S, et al
    Nox2+ Myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
    Cardiovasc Res. 2020 Feb 20. pii: 5741408. doi: 10.1093.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.